Screener
ANI Pharmaceuticals ANIP EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from ANI Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's EBITDA margin?
- ANI Pharmaceuticals (ANIP) reported EBITDA margin of 24.1% in Q2 2026.
- How has ANI Pharmaceuticals's EBITDA margin changed year-over-year?
- ANI Pharmaceuticals's EBITDA margin increased by 114.0% year-over-year, from 11.3% to 24.1%.
- What is the long-term trend for ANI Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's EBITDA margin has grown at a 10.8% compound annual growth rate (CAGR), from 13.7% to 22.9%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about ANI Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude